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Recombinant gamma interferon provokes resistance of human breast
cancer cells to spontaneous and IL-2 activated non-MHC restricted
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Summary Natural and lymphokine activated killer cells (NK and LAK) are believed to play an important
role in the control of tumour progression and metastasis. Their specific receptors on tumours cells are still
unknown. Several studies suggest that these cells recognise and eliminate abnormal cells with deleted or
reduced expression of MHC class I molecules. Previous reports suggest that interferons (IFN), by increasing
MHC class I expression on target cells, induce resistance to killing by NK cells. We investigated the role of
MHC molecule expression by two human breast cancer cell lines T47D and ZR75-1 in their susceptibility to
NK and LAK cells. These two cell lines spontaneously express low levels of HLA class I antigens but no HLA
class II molecules. After IFN-y treatment they both overexpressed MHC class I and de novo expressed class 11
molecules as detected by flow cytometry, quantified by a radioimmunoassay and analysed by two-dimensional
gel electrophoresis. Opposed to untreated cells these IFN-y treated cells were resistant to NK and LAK lysis.
Furthermore, preincubation of IFN-y treated breast cancer cells with F(ab')2 fragments of monoclonal
antibodies to HLA class I and HLA class II molecules was unable to restore lysis. In contrast, several
complete monoclonal antibodies including anti-HLA class I and HLA class 11 induced the lysis of target cells
whether or not they had been treated by IFN-y. The therapeutic use of monoclonal antibodies directed against
antigens expressed on tumour cells (ADCC) in conjunction with interferon therapy should be discussed in
lymphokine-based strategies for treatment of cancer patients.
Natural killer (NK) cells are a phenotypically heterogeneous
effector subpopulation of lymphocytes, with large azurophilic
granules in their cytoplasm. NK cells display a spontaneous
cytotoxicity against a variety of tumour cells (Herberman,
1986), virus infected cells and some normal cells in bone
marrow and thymus. In vitro NK activity can be measured
against K562 cells, classical targets which lack class I and
class II MHC gene products on their surface (Ythier &
Hercend, 1986). Interferons, TNF-a and IL-2 are potent
inducers of NK activity (Itoh et al., 1985; Ostensen et al.,
1987; Burns et al., 1985).
Lymphocyte activated killer (LAK) cells obtained after
3-5 days of culture of PBL in the presence of 2-3 ng ml-'
IL-2, are able to kill a wide variety of established cell lines,
autologous and allogeneic fresh tumour cells and cells which
are resistant to NK cytolysis (Grimm et al., 1982).
NK and LAK cells are believed to play an important role
in the control of tumour progression and metastasis. They
are distinct from immune cytotoxic T lymphocytes, since they
are spontaneously lytic to target cells lacking MHC gene
products. Their specific receptors for tumours cells are still
unknown and probably distinct from the T cell receptor
(Herberman, 1986). Several studies suggest that these cells
recognize and eliminate abnormal cells with deleted or
reduced expression of MHC class I molecules (Storkus et al.,
1987). Previous reports suggest that a and y interferons, by
increasing MHC class I expression in target cells, induce
resistance to killing by NK cells (Taniguchi et al., 1987). In
this paper we report the effect of gamma interferon on MHC
class I and II expression in two human breast cancer cell
lines and upon their susceptibility to killing by NK and LAK
cells. We, thus, tested the role of HLA class I and II in
tumour cells cytolysis.
Materials and methods
Reagents
Purified human recombinant gamma interferon with specific
activity of 2 x 107 U mg-' protein, was kindly provided by
Dr M. Brandely (Roussel Uclaf Laboratories).
Highly purified human interleukin-2 prepared from normal
peripheral blood cell cultures (Banque du Sang, H6pital
Saint Louis) was used at a final concentration of 2.7 ng ml-'.
In some experiments, recombinant human IL-2 from
Roussel-Uclaf was also used and gave comparable results.
Target cells
Two metastatic human breast adenocarcinoma cell lines were
tested: T47D (Keydar et al., 1979) and ZR75-1 (Engel et al.,
1978). Both cell lines were cultured in DMEM (Gibco)
supplemented with 10% heat inactivated fetal calf serum,
2 mM L-glutamine.
Monoclonal antibodies (MoAb)
MoAb M28 is an IgG2a which recognises 02 microglobin
(O2M) at the cell surface (Fellous et al., 1981). MoAb W6-32
(IgG2a) recognises a framework determinant of HLA A,B,C
heavy chain (Barnstable et al., 1978). MoAb D1-12 (IgG2a)
is an anti-HLA class II directed to a monomorphic deter-
minant of DR locus (Carrel et al., 1981). MoAb H6F3 is
directed against transferrin receptor. These antibodies were
used as ascitic fluids or as purified F(ab')2 fragments. F(ab')2
fragments were isolated, after digestion of the antibodies with
pepsin, by chromatography on protein A. Indirect immuno-
fluorescence was then performed with the F(ab')2 fragments
on T47D and ZR75-1 cell lines, analysed using flow cyto-
metry in order to determine the concentration equivalent to
maximal binding observed with intact antibodies. Mouse
monoclonal antibody to CMV was used as negative control.
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Radioimmunoassay on live cells
Cell suspensions were incubated with saturating concentra-
tions of the specific MoAb (106 cells in 100iLl total volume at
4°C for 1 h), then washed twice in PBS-BSA-azide and
incubated with a F(ab')2 1251 iodinated goat anti-mouse Ig
antibody (1/50 dilution of mg ml-' antibody solution at
4°C for 1 h). Specific radioactivity bound per 106 cells was
determined by an LKB gamma counter after three washes in
buffer. Non-specific binding (negative control) was sub-
tracted.
Two-dimensional gel electrophoresis
Two-dimensional gel electrophoresis of class I and class II
molecules was performed on the two cancer cell lines after
culture with or without IFN-y (1,000 U ml-' for 48 h). Some
4 x 107 control cells and 4 x 107 treated T47D and ZR75-1
cells were incubated for 4 h at 37°C in 2 ml of methionine-
free RPMI 1640 supplemented with 5% dialysed FCS and
400 yiCi of 35S-methionine (Amersham-France); washed
radiolabelled cells were extracted with 400 .lI of 0.5%
Nonidet P40 (NP-40) for 30 min at 4°C and extracts were
then centrifuged at l1,000 g for 5 min. A 400 itl aliquot of
the NP-40 extracts was precleared with 400 of Staphylococ-
cus aureus cowan I strain protein A (Staph-A) for 30 min at
4°C. Specific radiolabelled cell proteins were then immuno-
precipitated by the addition of 10pl of Staph-A precleared
extracts for 120 min. Antigen-antibody complexes were
eluted with 30 jl of electrofocusing sample buffer. Super-
natant was kept frozen at - 80°C until use. Samples were
prepared according to the technique described by Laemmli
(1970) and adapted by O'Farrel (1975) and O'Farrel et al.
(1977). In the first dimension, the proteins were separated
according to their charges using a non equilibrium pH
gradient electrophoresis (NEPHGE). The second dimension
was run in 10% acrylamide slab gel (Charron & McDevitt,
1980).
Microcytotoxicity assays (NK and LAK assays)
For NK cytolysis assays, peripheral blood lymphocytes
(PBL) from normal human volunteers (from the Centre de
Transfusion Sanguine, Hopital Saint Louis, Paris) were
isolated on ficoll-hypaque (MSL, Eurobio, Paris) washed and
depleted of adherent cells by 1 h incubation in plastic Petri
dishes. For lymphokine induction of activated killer cells,
PBL from human volunteers were cultured for 3 days at 106
cells per ml in RPMI medium, supplemented with 10% FCS
and recombinant IL-2 (2.7 ng ml-') and washed before use.
Serial dilutions of effector cells were distributed in round
bottom microtitre plates in RPMI medium supplemented
with 10% FCS (each dilution was performed in triplicate).
Target cells were cultured for 48 h in the presence or absence
of 1,000 U ml-' recombinant IFN-y, labelled with 200 liCi of
5'Cr (sodium chromate, Amersham) for 1 h and washed three
times. 5'Cr labelled cells (I04 in 200pl) were added to each
well. Spontaneous and total release were measured in quad-
ruplicate in wells receiving no effector plus medium and 1 M
HCI respectively. Plates were incubated for 4 h at 37°C for
NK and LAK cytotoxic assays. Supernatants were collected
by using a skatron device (Skatron Lier, Norway) and 5'Cr
release was measured in a Kontron y counter. Percent-
age of specific lysis was calculated as follows: % of specific
lysis = [(sample release - spontaneous release) / total re-
lease - spontaneous release)] x 100. For experiments using
F(ab')2 fragments of W6-32 (anti-class I), D1-12 (anti-class
II), M28 (anti-P2 microglobulin) and H6F3 (anti-transferrin
receptor) monoclonal antibodies, target cells were incubated
with 20 fig ml ' antibodies during the 1 h period of 5'Cr
labelling. Experiments with complete antibodies were per-
formed as with F(ab')2; IFN-y treated target cells and
untreated target cells were incubated with ascites fluid con-
taining 20 ig ml-' monoclonal antibody.
Results
Expression ofHLA class I and II antigen
Membrane expression of HLA class I and II determinants
was studied by radioimmunoassay of live cells using MoAb
directed against monomorphic determinant.
As shown in Table I, both cell lines spontaneously have
low reactivity to W6-32 MoAb. No reactivity was observed
with D1-12 MoAb, directed against the HLA DR Locus.
After IFN-' treatment (1000 U ml', 48 h), HLA class I
expression was increased in both cell lines and expression of
HLA DR determinants was induced.
2D gel electrophoresis
Biosynthesis of HLA molecules was studied in the two cell
lines (Figure 1). 2D gel analysis of HLA class I molecules in
untreated cells presented a complex pattern including a set
of spots at 44 kDa corresponding to the heavy chain(s) and
one spot at 12 kDa corresponding to P2M. IFN-y treatment
induced an increase in biosynthesis of these molecules.
Before treatment, immunoprecipitation using Dl-12 MoAb
failed to show any spot in the molecular weight range corres-
ponding to HLA DR.
After IFN-1 treatment (1,000 U ml-', 48 h), 2D gel ana-
lysis revealed the classical profile of human heterodimeric
molecules including an acidic a chain of 32-34 kDa, a more
basic 27-29 P chain and a 31 kDa molecule corresponding to
the invariant chain (Ii).
NK activity
The susceptibility of untreated and IFN-y treated breast
cancer cells to non-MHC restricted cytotoxicity were com-
pared. Their susceptibility to NK lysis was first tested, using,
as effector cells, freshly separated normal human lympho-
cytes in a 4 h chromium release assay. As shown in Figure 2,
40% of either T47D (panel a) or ZR75-1 (panel b) cells were
lysed by normal PBL at a 200:1 effector to target cell ratio.
IFN-y treated cells were poorly lysed at this high a dilution.
Similar results with small variations of lysis intensity were
observed independent of the blood donor (not shown).
LAK activity
The activated IL-2 cells were used as effectors in a 4 h
chromium release assay at a maximum effector-to-target ratio
of 25:1. As shown in Figure 2, untreated breast cancer cells
were more susceptible to LAK lysis than IFN-'y treated cells.
This result was found with the two cell lines tested, T47D
(panel c) and ZR75-1 (panel d). Several experiments with
other effector cell-donors have given identical results (not
shown).
Modulation oftarget lysis by anti-HLA class I antibody
To test whether induction of HLA class I molecules was
responsible for resistance to the non MHC restricted cytotox-
icity, the ability to restore lysis by masking these molecules
Table I Expression of MHC molecules on human breast cancer cell
lines, T47D and ZR75-1, and their modulation by y interferon
Cell lines
T47D ZR75-1
Control IFNy Control IFNy
W6-32Ab 12,560 33,640 6,680 61,350
DI-12Ab 2,870 25,260 720 33,840
Values indicate optimal binding at the plateau dilutions of W6-32
(anti-HLA class I) and DI-12 (anti-HLA class II) monoclonal anti-
bodies (10-3 dilution) as determined using a radioimmunoassay on live
cells. Results are expressed as specific c.p.m. bound per 106 cells. Mean
ofthreedifferentexperimentsintriplicate. s.d. areusuallylessthan 10%.560 N. JABRANE-FERRET et al.
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Figure 1 Two-dimensional gel electrophoresis showing HLA class I and HLA class 11 expression in cells with or without IFN-y
(1000 U ml-' for 48 h) treatment. I and II: Immunoprecipitation with W6-32 MoAb of T47D (I) and ZR75-1 (II) cells. a, untreated
control; b, cells treated for 48 h with 1,000 U ml' IFN-y. The 12 kDa spot is P2 microglobulin, the 44 kDa set of spots represent
heavy chain-class I molecules (HC). III and IV: immunoprecipitation with DI-12 MoAb of T47D (III) and ZR75-1 (IV) cells. a,
untreated control; b, cells treated for 48 h with 1,000 U ml-' IFN-y revealing the profile of human DR heterodimer with the acidic
a chain (a: 32-34 kDa), the basic P chain (P: 27-29 kDa) and the invariant chain (li: 31 kDa). A is actin.
with F(ab')2 fragments prepared from W6-32 antibody was
tested.
F(ab')2 prepared from anti-HLA class II, Dl-12, anti
transferrin receptor, H6F3 and anti-A2M, M28, MoAbs were
used as controls.
As shown in Figure 3 the F(ab')2 fragments from neither
W6-32 or the control antibodies restored the susceptibility to
lysis of IFN-y treated cells to NK and LAK effectors (T47D
panels a and c, ZR75-1 panels b and d).
Similar experiments using complete antibodies gave very
different results. All the antibodies tested increased the lysis
of IFN-y treated breast cancer cells to both NK and LAK
mediated cytotoxicity (Figure 2). The previous results were
obtained either by preincubating target cells with antibodies
or by the addition of antibodies during the 4 h microcytotox-
icity assay.
Discussion
We report data on two metastatic human breast carcinoma
cell lines which spontaneously express low levels of HLA
class I molecules and do not express HLA class II. These two
cell lines are NK and LAK sensitive. Pretreatment of these
two target cells with IFN-y induced a dramatic increase of
HLA class I expression and de novo membrane expression of
HLA class II molecules. This synthesis was studied at mem-
brane and protein levels. IFN-y treatment induced an in-
creased resistance of target cells to NK and LAK lysis.
The molecular mechanisms of target recognition and lysis
by the non-MHC restricted cytotoxic effector cells remain
controversial. Previous results in animal (Karre et al., 1986)
and human (Storkus et al., 1987; Harel-Bellan et al., 1986)
cell lines suggest an inverse relationship between the degree
of HLA class I expression and susceptibility to NK or LAK.
These effector cells may recognise the loss, or reduced expres-
sion, of HLA class I antigens as being abnormal. More
recently Quillet et al. (1988) reported, based on gene trans-
fection studies, that the non-MHC restricted cytotoxic NK
and LAK cells are capable of discriminating between HLA
class l+ and HLA class I- Daudi cells. Results from other
laboratories favour this hypothesis; for instance, Lattime et
al. (1982) have reported a thymoma cell line variant in which
the loss of H-2 expression was also associated to a decrease
of LAK lysis. Opposite conclusions have been reported for a
variant of the Yac-I mouse cells, which express low levels of
H-2 markers but are insensitive to NK lysis (Dalianis et al.,
1981).
In our system IFN-y provoked an increase of HLA class I
expression at the surface of the breast cancer cells which was
associated with a decreased susceptibility to NK and LAK
cytolysis.
Nevertheless, masking the HLA class I determinants with
F(ab')2 fragments failed to modify the resistance induced by
IFN-y treatment, indicating that the increased HLA class I
expression is probably not directly responsible for NK and
LAK target recognition. This effect on susceptibility to lysis
could be related to effects on target molecules other than
MHC, since IFN--y is known to both stimulate and decrease
the synthesis of several proteins specifically (Adolf, 1985). It
has also been suggested that NK cells in man interact with
the transferrin receptor on tumour cells (Alarcon & Ferrat,
1985) and that mouse NK cells recognise the laminin recep-
tor on their targets, appearing to have a laminin-like sub-
stance on their surface (Hiserodt et al., 1985). IFN-y has
been recently shown to modulate tumour necrosis factor
receptor expression on epithelial cancer cells (Aggarwal et al.,
1985). However, the effect of IFN may be indirectly related
to HLA modulation. A very attractive hypothesis would be
that HLA class I molecules are in close association with NK
or LAK target structures. This hypothesis is substantiated by
a number of reports which indicated that several molecules
are associated with HLA class I at the cell surface, including
the insulin receptor (Chvatchko et al., 1983), the IL-2 recep-
tor (Szollosi et al., 1987) and the EGF receptor (Schreiber et
al., 1984), and are modulated by IFN-y (Pfeffer et al., 1987;
Zoon et al., 1986).
The intact IgG molecules of the same monoclonal anti-
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Figure 2 Chromium release cytolysis assay. a and b, NK cells; c
and d, LAK cells as effectors. a and c, T47D target cells; b and d,
ZR75-1 target cells. Percentage of specific lysis was calculated
as follows: % of specific lysis = [(sample release - spontaneous
release) / total release - spontaneous release)] x 100. For experi-
ments using W6-32 (anti-class I), DI-12 (anti-class II), M28
(anti-P2 microglobulin) and H6F3 (anti-transferrin receptor)
monoclonal antibodies, target cells were incubated with 20 jig
ml- antibodies during the I h period of 5"Cr labelling. 0l, Un-
treated target cells; *, IFN-y treated target cells. IFN-y treated
target cells preincubated with W6-32 (U), D1-12 (O), H6F3 (U),
M28 (0) monoclonal antibodies.
bodies, directed to HLA class I, HLA class II, P2M and
transferrin receptors, induced lysis by normal PBL. These
results are most likely explained by an antibody dependent
cellular cytotoxicity phenomenon (ADCC), since the NK and
LAK effector cells also bear the receptor for the Fc fragment
of immunoglobulin (CD16+).
Finally our results may have clinical importance since
IFN-y is currently co-administered with IL-2 in tumour-
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Figure 3 The chromium release cytolysis assay was performed as
in Figure 2. a and b, NK cells; c and d, LAK cells as effectors. a
and c, T47D cell targets; b and d, ZR75-1 cell targets. Experi-
ments with F(ab')2 fragments were performed as above: E0,
untreated target cells; *, IFN-y treated target cells, IFN-y
treated target cells preincubated with purified (Fab')2 monoclonal
antibodies, W6-32 (U), Dl-12 (O), H6F3 (U) M28 (0).
bearing patients and ADCC could be a component of an
interleukin-2 LAK-based treatment strategy (Herberman et
al., 1979).
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